Gary Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace was Director of QRxPharma Ltd (ASX: QRX) from 2001 through 2014. He is currently a Director of ResMed Inc. (NYSE: RMD) and Transition Therapeutics Inc (TSX: TTH). He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 50 research papers, reviews and patents. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Bachelor of Science (Honors) from the University of New South Wales and a PhD from MIT, where he was a Fulbright Scholar. Gary Pace is a seasoned biopharmaceutical executive with over 30 years of experience in the industry. He has co-founded a number of early stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace was Director of QRxPharma Ltd (ASX: QRX) from 2001 through 2014. He is currently a Director of ResMed Inc. (NYSE: RMD) and Transition Therapeutics Inc (TSX: TTH). He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 50 research papers, reviews and patents. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Bachelor of Science (Honors) from the University of New South Wales and a PhD from MIT, where he was a Fulbright Scholar.

Oncology